



1/15/09 | Press Release

DAVA announces the approval and launch of Amoxicillin Tablets USP, 875 mg

Fort Lee, New Jersey, January 15, 2009 – DAVA Pharmaceuticals, Inc. (“DAVA”) is proud to announce its receipt of U.S. Food and Drug Administration approval of Amoxicillin Tablets USP, 875mg. Amoxicillin 875mg is the AB-rated bio-equivalent version of GlaxoSmithKline’s Amoxcil[®]. The approval completes the full line of the Amoxicillin family of products offered by DAVA. DAVA’s Amoxicillin 875mg is available for immediate delivery.

DAVA Pharmaceuticals Inc., a specialty pharmaceuticals company, is focused on developing and marketing a broad portfolio of pharmaceutical products. DAVA is aggressively building its product portfolio through a combination of acquisitions, strategic alliances, in-licensing transactions, partnerships and development. DAVA’s headquarters is in Fort Lee, New Jersey. For further information, please visit DAVA’s website located at www.davapharma.com.